1 report

  • Synergys Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details
  • LICENSING AGREEMENTS

It is a fully human dual-targeting monoclonal antibody which acts by targeting angiopoietin-## (Ang-##) and angiopoietin-## (Ang-##).

  • Biotherapeutic
  • Cancer
  • United States
  • Deals & Alliance
  • Synergys Biotherapeutics, Inc.